Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN57354520

Enrollment

Registered

2006-03-29

Start date

2006-02-10

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction Circulatory System Myocardial infarction

Interventions

Allopurinol versus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Post myocardial infarction - days 3 to 14

Exclusion criteria

Exclusion criteria: 1. Renal failure 2. Concomitant warfarin therapy 3. Allopurinol allergy

Design outcomes

Primary

Measure	Time frame
Assessment of remodelling	—

Secondary

Measure	Time frame
Brain natriuretic peptide (BNP)	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026